OnCusp Therapeutics bets on the hardest handoff in cancer medicine

A molecule can look magnificent in a laboratory and disappoint in a patient. OnCusp Therapeutics has built its business around that awkward crossing, with a CDH6-targeting cancer drug now producing early clinical evidence.